Semaglutide denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Semaglutide

Step therapy (also called "fail-first") requires patients to try one or more less-expensive or preferred drugs before the plan will cover semaglutide. UnitedHealthcare's step-therapy protocols for this class of medication typically require documented evidence that the patient has tried and failed — or has a documented contraindication to — the specified step drugs listed in the plan's coverage policy.

This denial is among the most successfully appealed categories when the patient has a relevant prior-treatment history, an existing clinical reason to bypass the step, or when step-therapy override laws apply.

## Federal Appeal Framework

• Internal appeal + step-therapy exception — file a formal internal appeal and, simultaneously, a step-therapy exception request. Many states have enacted step-therapy override laws requiring plans to grant exceptions when certain clinical criteria are met; verify whether your state's law applies to your plan type.
• ERISA §503 (full-and-fair review) — ERISA-governed plans must provide a full-and-fair review of your appeal, with a decision typically within 30 days for pre-service standard appeals and 72 hours for urgent/expedited.
• External review (ACA §2719) — after exhausting internal appeals, independent external review is available. The external-review window is generally approximately four months from the original denial. Expedited review is available for urgent clinical situations.

## Documentation to Gather

• UnitedHealthcare's current step-therapy/coverage policy for semaglutide — identify every required step drug and every stated exception criterion.
• Prior-treatment history with dates and outcomes — for each required step drug, provide: the drug name, the dates it was prescribed, the dose used (from your records), and the reason it was discontinued (inadequate response, side effects, contraindication).
• Prescriber letter of medical necessity — the prescriber should explain why semaglutide is the appropriate therapy now, why the required step drugs are not appropriate for this patient, and cite any relevant guideline organization's position (e.g., applicable ADA, AACE, ACC, or Obesity Medicine Association guidance).
• Clinical severity documentation — chart notes demonstrating the patient's current clinical status and the risk of delaying appropriate therapy.
• Applicable state step-therapy override law — if your state has one, attach the statutory or regulatory citation in your appeal letter.

## Criteria-Mapping Structure

| Step Required by UHC | Tried / Reason Not Applicable | |---|---| | [Step drug 1 from policy] | [Dates tried, outcome, or documented reason to skip] | | [Step drug 2 from policy] | [Same format] | | Exception criterion (if applicable) | [Chart fact satisfying the exception] |

## Key Argument

Step therapy exists to ensure cost-effective sequencing — not to deny clinically necessary care indefinitely. If the patient has already tried the required steps, the denial should be reversed on the basis of documented treatment failure. If an exception applies (clinical contraindication, rapid disease progression, prior treatment history from another plan), document it precisely and cite the insurer's own exception criteria back to them.